Novo Nordisk Shares Slump on Pipeline, Pricing Grilling — SkimNews
Get the Finance newsletter
Daily finance — markets, central banks, M&A, the prints that move money. Free.
- Novo Nordisk shares slumped as management was grilled by investors on pricing and M&A strategy at a public forum.
- The company outlined plans for new drugs to boost sales, but investors remained wary amid pipeline concerns the CEO identified as a main problem.
Why it matters: When investor grilling on pricing and pipeline gaps drives a stock sell-off despite new drug promises, it signals that Novo's growth narrative is being repriced — markets are demanding proof that the next leg of Wegovy/Ozempic-era growth is real.
Ask SkimNews
